Metrics from July 8, 2011 to March 31, 2012

ACTIVITY REPORT: MARCH 2012 METRICS FROM JULY 8, 2011 TO MARCH 31, 2012

GRANT ID: 7796 TEVA NEUROSCIENCE

Living Medical eTextbook: Neurology: Parkinson’s Disease Edition: Early Diagnosis and Management

DESCRIPTION: Parkinson's disease is traditionally diagnosed clinically based on classic motor symptoms of tremor, rigidity, bradykinesia, and postural instability. However, it is increasingly recognized that motor symptoms are only one manifestation of this chronic neurodegenerative disease— and a late manifestation at that. The Parkinson's Disease Edition of the Living Medical Textbook describes the symptoms of Parkinson's disease, the underlying pathophysiology, and available treatments for Parkinson's disease. Hyperlinks throughout the chapter lead the reader to more detailed and specific information on these topics from a variety of sources on the Internet in a multitude of formats. The first chapter sets the stage for a discussion of clinical trials and the neuroprotective potential of monoamine oxidase type B inhibitors in the management of early, moderate and advanced Parkinson’s disease.

FUNDERS:  TEVA Neuroscience

URL ADDRESS: http://lmt.projectsinknowledge.com/Activity/index.cfm?jn=2027

POSTED ACTIVITIES: Chapter 1 Parkinson’s Disease: Early Diagnosis Editor-In-Chief: Robert A. Hauser, MD, MBA Contributing Editor: Mark F. Lew, MD Release Date: July 8, 2011

Chapter 2 Clinical Trial Design in Parkinson’s Disease Editor-In-Chief: Robert A. Hauser, MD, MBA Release Date: July 8, 2011

Chapter 3 MAO-B Inhibitors in Parkinson’s Disease: Evaluating the Evidence for Neuroprotection Editor-In-Chief: Robert A. Hauser, MD, MBA Release Date: July 8, 2011 Chapter 4 Management of Early-Stage Parkinson’s Disease Editor-In-Chief: Robert A. Hauser, MD, MBA Release Date: July 28, 2011

Chapter 5 Management of Moderate-to Advanced-Stage Parkinson’s Disease Editor-In-Chief: Robert A. Hauser, MD, MBA Contributing Editor: Rajesh Pahwa, MD Release Date: August 26, 2011

Chapter 6 Management of Nonmotor Symptoms of Parkinson’s Disease Editor-In-Chief: Robert A. Hauser, MD, MBA Contributing Editor: Shilpa Chitnis, MD, PhD Release Date: October 26, 2011

READERSHIP:

METRICS FROM JULY 8, 2011 TO MARCH 31, 2012

CURRENT SERIES WEBSITE READERS (PARTICIPANTS) 13,539 CURRENT SERIES APP DOWNLOADS 8,137 CURRENT SERIES TOTAL READERS (DOWNLOADS AND 21,676 WEBSITE) % OF CME CERTIFICATES 5% COMPLETION AVERAGE TIME IN MINUTES 17:47 TOTAL PAGEVIEWS 28,018

METRICS FROM APRIL 7, 2010 TO MARCH 31, 2012

TOTAL PROGRAM WEBSITE READERS 20,240 TOTAL PROGRAM APP DOWNLOADS 14,205 TOTAL PROGRAM READERSHIP (DOWNLOADS AND 34,445 WEBSITE)

PROJECTS IN KNOWLEDGE TEVA NEUROSCIENCE 2 CONFIDENTIAL LMT-PARKINSON’S DISEASE MONTHLY REPORT APRIL 19, 2012 ACTIVITY 2027 CLARIFICATION ON READERSHIP METRICS: Our depth of visit is comparatively understated; the Projects In Knowledge site is built to server dynamic content, whereby the visitor can scroll through our activity in a continuous uninterrupted flow. What would appear in other websites as multiple pages, and encourages the reader to “hit”, next tends to inflate the actual level of participation. Therefore, our metrics reflect true readership of content and depth of participation

SATISFACTION PERFORMANCE INDICATOR: Satisfaction performance indicators demonstrate the strength of our programs to deliver critical components of medical education. The PD LMeT continues to received high levels of satisfaction on the following measures:  All participants (98%) felt that we supported the learning objective.  Participants indicated that the material was “just right” (92%).  According to our participants we consistently present material that is considered “free of bias” (99%).

LEARNING OBJECTIVES:  Understand the importance of early diagnosis, the need to treat early, and the preclinical features of Parkinson’s disease.  Analyze current therapies and combinations in the treatment of patients with Parkinson’s disease.  Define and create awareness of clinical trials focusing on disease progression.  Educate on Delayed Start Trials and other disease modification trials.  Understand results of clinical trials assessing disease modification with MAO-B inhibitors.

PROJECTS IN KNOWLEDGE TEVA NEUROSCIENCE 3 CONFIDENTIAL LMT-PARKINSON’S DISEASE MONTHLY REPORT APRIL 19, 2012 ACTIVITY 2027 TARGET AUDIENCE: This CME/CE activity is designed for Parkinson’s disease physician specialists, community neurologists, Parkinson’s disease nurse specialists, and pharmacists.

PROMOTION:  E-mail to Projects In Knowledge database, which include: previous live activity attendees, those who have indicated interest in receiving e-mails about activities in this therapeutic area, members of our Education Initiative, and learners from online activities  Each activity is featured in a dedicated e-mail campaign announcing its release. Repeated exposure to the course offerings increases participation and implementation. Additional cross promotion within each therapeutic category.  Google Ad Words, SEO, and viral marketing campaign  Promotion through banner ads, strategiacally-placed links, and membership emails (eg, CMEList.com, CE Search Engine, etc) to increase exposure

PROJECTS IN KNOWLEDGE TEVA NEUROSCIENCE 4 CONFIDENTIAL LMT-PARKINSON’S DISEASE MONTHLY REPORT APRIL 19, 2012 ACTIVITY 2027  Facebook, Twitter, Linked In, and other social networking strategies to facilitate clinician access to online and/or mobile content

CONTENT:  6 Chapters (1 chapter with 1.0 credits and 5 chapters with 2 credits each)

FACULTY:  Editor-In-Chief – Robert A. Hauser, MD, MBA  Contributing Editor – Shilpa Chitnis, MD, PhD, Mark F. Lew, MD, and Rajesh Pahwa, MD

CREDITS:  11 CME/CPE/CE total credits for participation in all chapters.

PROJECTS IN KNOWLEDGE TEVA NEUROSCIENCE 5 CONFIDENTIAL LMT-PARKINSON’S DISEASE MONTHLY REPORT APRIL 19, 2012 ACTIVITY 2027